Form 4: Niagen Bioscience Director Acquires Stock Options

Frank L. Jaksch Jr., Director at Niagen Bioscience, Inc., acquired 31,746 stock options with an exercise price of $3.45.

Summary

• Frank L. Jaksch Jr., a Director at Niagen Bioscience, Inc. (NAGE), has acquired 31,746 stock options.
• The transaction occurred on June 24, 2026, with the options having an exercise price of $3.45.
• These options are exercisable starting June 24, 2027, and expire on June 23, 2036.
• The underlying securities are 31,746 shares of Common Stock.
• Following this transaction, Jaksch beneficially owns 31,746 shares of Common Stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates a director's commitment and potential belief in future stock appreciation, but it does not represent new capital for the company.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price suggests a potential for future value appreciation.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future performance, as the value of these options is tied to the stock price.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to incentivize management and align their interests with shareholders, particularly for companies like Niagen Bioscience that may be in development or growth phases.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively, suggesting confidence in future stock performance. However, it does not immediately impact share price or provide new capital.

Next Steps

• The stock options will vest on June 24, 2027.
• The options will expire on June 23, 2036.

Key Dates

Keywords

stock options, insider trading, Niagen Bioscience, NAGE, director, beneficial ownership, SEC Form 4